These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30591748)

  • 1. XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America.
    Martínez CAA; Lanas F; Radaideh G; Kharabsheh SM; Lambelet M; Viaud MAL; Ziadeh NS; Turpie AGG;
    Egypt Heart J; 2018 Dec; 70(4):307-313. PubMed ID: 30591748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global Prospective Safety Analysis of Rivaroxaban.
    Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ;
    J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia.
    Kim YH; Shim J; Tsai CT; Wang CC; Vilela G; Muengtaweepongsa S; Kurniawan M; Maskon O; Li Fern H; Nguyen TH; Thanachartwet T; Sim K; Camm AJ;
    J Arrhythm; 2018 Aug; 34(4):418-427. PubMed ID: 30167013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Kuhls S; van Eickels M; Turpie AG;
    Eur Heart J; 2016 Apr; 37(14):1145-53. PubMed ID: 26330425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
    Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
    Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG
    Europace; 2019 Mar; 21(3):421-427. PubMed ID: 30052894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort study.
    Bonnemeier H; Huelsebeck M; Kloss S
    Int J Cardiol Heart Vasc; 2019 Jun; 23():100367. PubMed ID: 31111087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.
    Liu PY; Choi EK; Kim TS; Kuo JY; Lee JM; On YK; Park SW; Park HW; Shin DG; Wang L; Yen HW; Lee MH;
    Adv Ther; 2022 Jul; 39(7):3316-3333. PubMed ID: 35616848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.
    Pisters R; van Vugt SPG; Brouwer MA; Elvan A; Ten Holt WL; Zwart PAG; Kirchhof P; Crijns HJGM; Hemels MEW
    Neth Heart J; 2017 Oct; 25(10):551-558. PubMed ID: 28674871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.
    Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG; Camm AJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):70-79. PubMed ID: 30423165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
    Shimokawa H; Yamashita T; Uchiyama S; Kitazono T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Sakuma I; Saku K; Okumura Y; Nakamura Y; Morimoto H; Matsumoto N; Tsuchida A; Ako J; Sugishita N; Shimizu S; Atarashi H; Inoue H
    Int J Cardiol; 2018 May; 258():126-132. PubMed ID: 29429636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
    Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Iwashiro S; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Thromb Thrombolysis; 2019 Nov; 48(4):653-660. PubMed ID: 31432451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea.
    Shim J; On YK; Kwon SU; Nam GB; Lee MH; Park HW; Hong KS; Kim NH; Amarenco P; Rha SW; Shin DG; Rha JH; Kim YH
    Korean J Intern Med; 2021 Jul; 36(4):906-913. PubMed ID: 32872740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia.
    Alosaimi HM; Alqahtani S; Balkhi B; Alqahtani M; Alzamil F; Alhossan A; Alqahtany FS; Alharbi AA; Alqahtani NA; Albackr H; Elgohary G; Algahtani FH
    PeerJ; 2022; 10():e13974. PubMed ID: 36105646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
    Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
    ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.
    Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Jan; 34(1):141-150. PubMed ID: 29980835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.